Pleasantville, NY, United States of America

Keith Crosby

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Keith Crosby

Introduction

Keith Crosby is an accomplished inventor based in Pleasantville, NY (US). He has made significant contributions to the field of biotechnology, particularly in the development of non-human animal models for research purposes. His work focuses on the human transthyretin protein and its implications for medical research.

Latest Patents

Crosby holds a patent titled "Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use." This patent involves non-human animal cells and non-human animals that express a human transthyretin protein or a chimeric transthyretin protein. The methods outlined in the patent are designed to assess the in vivo efficacy of human-TTR-targeting reagents, such as nuclease agents aimed at human TTR. He has 1 patent to his name.

Career Highlights

Keith Crosby is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to advance his research in the field. His work has been instrumental in developing innovative solutions that enhance our understanding of human diseases and potential treatments.

Collaborations

Crosby collaborates with notable colleagues, including Jeffery Haines and Meghan Drummond Samuelson. Their combined expertise contributes to the success of their projects and the advancement of their research goals.

Conclusion

Keith Crosby's innovative work in biotechnology and his patent contributions highlight his role as a significant figure in the field. His research continues to pave the way for advancements in medical science and therapeutic development.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…